What's the difference between thymosin alpha-1 and thymosin beta-4, and which does what?

The short answer

The names are nearly identical, which causes constant confusion — but thymosin alpha-1 and thymosin beta-4 are unrelated peptides that do completely different jobs.

Evidence tier framing: Thymosin alpha-1 is Tier 2 (multiple RCTs, approvals abroad for hepatitis and as a vaccine adjuvant). Thymosin beta-4 and its fragment TB-500 are Tier 4 (mostly preclinical tissue-repair data, no major human outcome trials).

The distinction in one line each:

• Thymosin alpha-1 (Tα1) — a 28-amino-acid immune modulator; the best-evidenced immune peptide
• Thymosin beta-4 (Tβ4) — a 43-amino-acid actin-regulating tissue-repair peptide; TB-500 is its synthetic fragment

Pick by goal: immune modulation (alpha-1) vs tissue repair and recovery (beta-4 / TB-500). They share a name root only because both came out of historical thymus-extract research. For the category overview see the immune & gut cornerstone.

Why the names mislead

Evidence tier: 2 — basic peptide biochemistry; the naming history is well documented.

Both peptides were originally isolated from thymus tissue fractions in the 1960s–70s, which is why they share the "thymosin" label and Greek-letter suffixes. But the naming reflects the fraction they were purified from, not any structural or functional relationship.

Thymosin alpha-1 is a small immune-signaling peptide. Thymosin beta-4 is a larger actin-sequestering protein involved in cell motility and tissue repair. They have different sequences, different receptors/targets, and different clinical rationales. Treating them as variants of one compound — which marketing sometimes does — is a category error.

Thymosin alpha-1 — immune modulation

Evidence tier: 2 — multiple RCTs and regulatory approvals abroad.

Thymosin alpha-1 enhances T-cell maturation and function, supports dendritic cells, and helps regulate immune response. It's approved in many countries (not the US) for hepatitis B and C, as a vaccine adjuvant, and in some cancer-supportive settings, and it was studied during COVID-19 (Romani 2012).

The key word is modulation — Tα1 regulates rather than blunt-boosts, which is what makes it relevant to immune balance rather than just amplification. It's the most genuinely evidenced peptide in the immune space. See our thymosin alpha-1 immune modulation article.

Thymosin beta-4 and TB-500 — tissue repair

Evidence tier: 4 — largely preclinical tissue-repair data.

Thymosin beta-4 regulates actin, the cytoskeletal protein central to cell movement and tissue repair. In animal models it supports wound healing, angiogenesis, and cardiac and other tissue recovery (Goldstein 2012 reviews the repair biology).

TB-500 is a synthetic fragment containing Tβ4's actin-binding active region, marketed for injury recovery and frequently discussed alongside BPC-157. The evidence is largely preclinical, and TB-500 lives squarely in the gray-market recovery space. See our TB-500 vs BPC-157 comparison.

Which one do I actually want?

Evidence tier: 3 — goal-matching grounded in each peptide's mechanism.

• Immune modulation / support during illness — Peptide: Thymosin alpha-1 · Evidence tier: 2
• Soft-tissue / injury recovery — Peptide: Thymosin beta-4 / TB-500 · Evidence tier: 4
• Hepatitis / vaccine-adjuvant context — Peptide: Thymosin alpha-1 (clinical, abroad) · Evidence tier: 2
• Wound healing (experimental) — Peptide: Thymosin beta-4 · Evidence tier: 4

If you're reaching for "thymosin" for immune reasons, you want alpha-1. If you're reaching for it for recovery from an injury, you want beta-4 / TB-500. They are not interchangeable, and the evidence behind alpha-1 is considerably stronger.

Limitations

This is an evidence comparison, not personalized medical advice.

• Thymosin alpha-1 is approved for specific indications abroad — not as general wellness immune support, and not FDA-approved in the US.
• Thymosin beta-4 / TB-500 evidence is preclinical — animal and mechanistic, not human outcome trials.
• Both are gray-market for most uses in the US; sourcing carries real risk. Verify via Finnrick.
• Immune and injury conditions warrant medical evaluation before self-treating.
• Pregnancy and breastfeeding are contraindications.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Same name root, different peptides. Thymosin alpha-1 is an immune modulator with real RCT evidence and approvals abroad — the strongest-evidenced immune peptide. Thymosin beta-4 (and its fragment TB-500) is a tissue-repair peptide with mostly preclinical data, used in the injury-recovery space. Choose by goal, and don't let the naming fool you into thinking they're versions of one compound.

Related on this site

• Peptides for immune & gut health (cornerstone)
• Thymosin alpha-1 immune modulation
• TB-500 vs BPC-157: when to stack
• Peptides for autoimmune conditions
• BPC-157 protocol guide
• Immune & Gut pillar hub
• Finnrick vendor testing

References

• Romani L, Bistoni F, Montagnoli C, et al. 2012. Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 1269:1-6. PMID 22871182 — thymosin alpha-1 immunoregulation.
• Goldstein AL, Hannappel E, Sosne G, Kleinman HK. 2012. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 12(1):37-51. PMID 22524423 — thymosin beta-4 tissue-repair biology.
• King RS, Newmark PA. 2012. The cell biology of regeneration. J Cell Biol. 196(5):553-562. PMID 22391035 — actin/cytoskeletal regulation in tissue repair (Tβ4 context).
• Garaci E, Pica F, Serafino A, et al. 2012. Thymosin α1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci. 1269:26-33. PMID 22592864 — thymosin alpha-1 immune-effector action.